Genmab — November 2015
-
personligt syntes jeg det er lidt skuffende, at ofa sc er udsat igenigen - men Novartis må jo mene det alvorligt, når de bruger så mange penge
-
tak for det sukkeralf
-
fra sibelius den 9/10 - We werein contact with Novartis yesterday and thecompanyconfirm that itplansto start twoph III trials in MS (likely RRMS and PPMS) in early 2016 and expectstolaunchthe drug inH2 2020.Novartis will pay low double-digit royalties(we expect 11-13%)to Genmab on sales.
-
castor fuldt rekrutteret
-
der er filet for dara rrmm
i canada -
det bliver dæl'me spændnede om de interím analyser bærer noget med sig
-
ud fra Davids gennemgang af operating cost lyder det ikke rigtig til at vi får en GEN-IND i går
-
går=år
-
EM1 duo fra JJ firmly slotted for 2015 clinic
-
will dose first patient 2015
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind